AstraZeneca, Daiichi Sankyo get FDA breakthrough therapy status for gastric cancer drug

This article was originally published here

Enhertu, a HER2-directed antibody drug conjugate (ADC), is being studied under a comprehensive development programme to assess the efficacy and safety of the monotherapy across multiple HER2-driven cancers

The post AstraZeneca, Daiichi Sankyo get FDA breakthrough therapy status for gastric cancer drug appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply